Fate Therapeutics announces proposed public ofering of common stock
Fate Therapeutics announced an underwritten public offering of its common stock. Fate Therapeutics intends to use net proceeds from the offering to fund clinical trials and nonclinical studies, manufacture of clinical product candidates and expansion of its cGMP compliant manufacturing operations. September 11, 2019